Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00090623 |
This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Condition | Intervention | Phase |
---|---|---|
Macular Degeneration |
Drug: rhuFab V2 (ranibizumab) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Safety/Efficacy Study |
Official Title: | A Phase IIIb, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects With Subfoveal Choroidal Neovascularization (CNV) With or Without Classic CNV Secondary to Age Related Macular Degeneration |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | FVF3192g |
Study First Received: | August 30, 2004 |
Last Updated: | September 1, 2009 |
ClinicalTrials.gov Identifier: | NCT00090623 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Subfoveal neovascular Age-related macular degeneration AMD Wet AMD |
Uveal Diseases Metaplasia Eye Diseases Choroid Diseases Neoplasm Metastasis |
Retinal Degeneration Macular Degeneration Neovascularization, Pathologic Retinal Diseases Choroidal Neovascularization |
Uveal Diseases Pathologic Processes Metaplasia Eye Diseases Choroid Diseases |
Retinal Degeneration Macular Degeneration Neovascularization, Pathologic Retinal Diseases Choroidal Neovascularization |